Intra Cellular Therapies Stock Fundamentals
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Intra Cellular's long-term financial health and intrinsic value.
Intra |
Intra Cellular Therapies Company Profit Margin Analysis
Intra Cellular's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Intra Cellular Profit Margin | (0.11) % |
Most of Intra Cellular's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Intra Cellular Therapies has a Profit Margin of -0.1097%. This is 99.02% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 91.36% lower than that of the firm.
Intra Cellular Therapies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intra Cellular's current stock value. Our valuation model uses many indicators to compare Intra Cellular value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intra Cellular competition to find correlations between indicators driving Intra Cellular's intrinsic value. More Info.Intra Cellular Therapies is rated fourth overall in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intra Cellular's earnings, one of the primary drivers of an investment's value.Intra Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.Intra Cellular is currently under evaluation in profit margin category among its peers.
Intra Fundamentals
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 2.67 M | |||
| Price To Earning | (6.56) X | |||
| Price To Book | 12.23 X | |||
| Price To Sales | 20.63 X | |||
| Revenue | 680.85 M | |||
| Gross Profit | 387.77 M | |||
| EBITDA | (116.72 M) | |||
| Net Income | (74.68 M) | |||
| Cash And Equivalents | 628.74 M | |||
| Cash Per Share | 6.64 X | |||
| Total Debt | 16.98 M | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 9.81 X | |||
| Book Value Per Share | 10.81 X | |||
| Cash Flow From Operations | (73.18 M) | |||
| Short Ratio | 1.20 X | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 132.0 | |||
| Number Of Employees | 860 | |||
| Beta | 0.46 | |||
| Market Capitalization | 14.05 B | |||
| Total Asset | 1.37 B | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 1.1 B | |||
| Current Asset | 541.82 M | |||
| Current Liabilities | 140.69 M | |||
| Net Asset | 1.37 B |
About Intra Cellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |